- $160.73m
- $135.71m
- $51.90m
- 96
- 20
- 62
- 62
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 40.76 | ||
| PEG Ratio (f) | 0.53 | ||
| EPS Growth (f) | 345.94% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 8.97 | ||
| Price to Tang. Book | 8.97 | ||
| Price to Free Cashflow | 19.53 | ||
| Price to Sales | 3.1 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -5.65% | ||
| Return on Equity | -7.2% | ||
| Operating Margin | -3.38% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 58.68 | 80.01 | 101.25 | 46.98 | 51.9 | 56.41 | 63.24 | 1.38% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +282.08 | -36.89 | -63.15 | n/a | n/a | +270.61 | +389.57 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
The Joint Corp. is an operator, manager and franchisor of chiropractic clinics that uses a private pay, non-insurance, cash-based model. The Company operates the Franchise Operations segment. The Company and its franchisees provide management services to affiliated professional chiropractic practices. The franchise system consists of approximately 842 clinics in operation. It offers a range of membership and wellness packages. It offers its patients the opportunity to visit its clinics without an appointment and receive prompt attention. Each patient's records are digitally updated for ready retrieval in its data storage system by its chiropractors in compliance with various applicable medical records security and privacy regulations.
Directors
- Peter Holt PRE (62)
- Jake Singleton CFO (39)
- Charles Nelles CTO
- Matthew Rubel LED (63)
- James Amos IND (75)
- Ronald DaVella IND (63)
- Suzanne Decker IND (59)
- Abe Hong IND (49)
- Glenn Krevlin IND (61)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- March 10th, 2010
- Public Since
- November 11th, 2014
- No. of Shareholders
- 36
- No. of Employees
- 443
- Sector
- Healthcare Providers & Services
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market- Shares in Issue
- 15,322,532
- Address
- 16767 N PERIMETER DRIVE, SUITE 240, SCOTTSDALE, 85260
- Web
- https://www.thejoint.com/
- Phone
- +1 4802455960
- Contact
- Kirsten Chapman
- Auditors
- BDO USA, LLP
Upcoming Events for JYNT
Q1 2025 Joint Corp Earnings Call
Joint Corp Annual Shareholders Meeting
Joint Corp Annual Shareholders Meeting
Q2 2025 Joint Corp Earnings Release
Similar to JYNT
ADVANCED BIOMED
NASDAQ Capital Market
IMEI Technology Health
NASDAQ Capital Market
Akanda
NASDAQ Capital Market
Astrana Health
NASDAQ Capital Market
Basel Medical
NASDAQ Capital Market
FAQ
What is the Joint share price?
As of Today at 21:27 UTC, shares in Joint are trading at $10.49. This share price information is delayed by 15 minutes.
How has the Joint share price performed this year?
Shares in Joint last closed at $10.49 and the price had moved by -13.16% over the past 365 days. In terms of relative price strength the Joint share price has underperformed the S&P500 Index by -19.85% over the past year.
What are the analyst and broker recommendations for Joint?
The overall consensus recommendation for Joint is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Joint dividend yield?
Joint does not currently pay a dividend.
Does Joint pay a dividend?
Joint does not currently pay a dividend.
When does Joint next pay dividends?
Joint does not currently pay a dividend.
How do I buy Joint shares?
To buy shares in Joint you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Joint?
As of the previous close price of $10.49, shares in Joint had a market capitalisation of $160.73m.
Where are Joint shares listed?
Here are the trading details for Joint:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: JYNT
What kind of share is Joint?
Based on an overall assessment of its quality, value and momentum Joint is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Joint share price forecast for 2025?
The analyst consensus target price for shares in Joint is $16.38. That is 56.15% above the last closing price of $10.49.
Analysts covering Joint currently have a consensus Earnings Per Share (EPS) forecast of $0.12 for the next financial year.
Find out moreWhat is the trend in the Joint share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Joint. Over the past six months, its share price has underperformed the S&P500 Index by -1.28%.
As of the last closing price of $10.49, shares in Joint were trading -8.47% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Joint PE Ratio?
The Joint PE ratio based on its reported earnings over the past 12 months is 40.76. The shares last closed at $10.49.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Joint?
Joint's management team is headed by:
- Peter Holt - PRE
- Jake Singleton - CFO
- Charles Nelles - CTO
- Matthew Rubel - LED
- James Amos - IND
- Ronald DaVella - IND
- Suzanne Decker - IND
- Abe Hong - IND
- Glenn Krevlin - IND